دورية أكاديمية
Prognostic factors in children and adolescents with differentiated thyroid cancer treated with total thyroidectomy and radioiodine therapy: a retrospective two-center study from China.
العنوان: | Prognostic factors in children and adolescents with differentiated thyroid cancer treated with total thyroidectomy and radioiodine therapy: a retrospective two-center study from China. |
---|---|
المؤلفون: | Wang C; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Li Y; Department of Radiology, Qingdao Women and Children's Hospital, Qingdao, Shandong, China., Wang G; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Liu X; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Zhang Y; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Lu C; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Li J; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Han N; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Wang Z; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Si Z; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Li F; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Lu G; Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China., Wang R; Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China., Wang X; Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. |
المصدر: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Jul 22; Vol. 15, pp. 1419141. Date of Electronic Publication: 2024 Jul 22 (Print Publication: 2024). |
نوع المنشور: | Journal Article; Multicenter Study |
اللغة: | English |
بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
مواضيع طبية MeSH: | Iodine Radioisotopes*/therapeutic use , Thyroidectomy* , Thyroid Neoplasms*/radiotherapy , Thyroid Neoplasms*/surgery , Thyroid Neoplasms*/pathology , Thyroid Neoplasms*/therapy, Humans ; Female ; Male ; Adolescent ; Retrospective Studies ; Prognosis ; Child ; China/epidemiology ; Follow-Up Studies ; Treatment Outcome ; Thyroglobulin/blood ; Combined Modality Therapy |
مستخلص: | Purpose: This two-center study aimed to explore the main prognostic factors affecting the final disease status in children and adolescents with differentiated thyroid cancer (caDTC) following total thyroidectomy and radioiodine therapy (RAIT). Materials and Methods: All caDTC patients from two centers in the period from 2004-2022 were retrospectively included. At the last follow-up, the patients' disease status was assessed and classified as an incomplete response (IR) or as an excellent or indeterminate response (EIDR). Then, the difference in preablation stimulated thyroglobulin (ps-Tg) levels between the two groups was compared, and the threshold for predicting IR was determined using receiver operating characteristic (ROC) analysis. Moreover, univariate and multivariate analyses were conducted to identify the factors influencing the patients' ultimate disease outcomes. Results: A total of 143 patients (98 females, 45 males; median age 16 years) were recruited. After a median follow-up of 42.9 months, 80 patients (55.9%) exhibited an EIDR, whereas 63 patients (44.1%) exhibited an IR. Patients with an IR had significantly greater ps-Tg levels than did those with an EIDR (median ps-Tg 79.2 ng/mL vs. 9.3 ng/mL, p<0.001). The ROC curve showed that ps-Tg ≥20 ng/mL was the most accurate for predicting IR at the last follow-up. According to multivariate analysis, only ps-Tg, T stage and the therapeutic response to initial RAIT were significantly associated with IR. Conclusion: In caDTC patients, the ps-Tg level, T stage, and response to initial RAIT are critical final outcome indicators. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Wang, Li, Wang, Liu, Zhang, Lu, Li, Han, Wang, Si, Li, Lu, Wang and Wang.) |
References: | Front Endocrinol (Lausanne). 2023 Aug 04;14:1217092. (PMID: 37600705) Front Pediatr. 2022 Sep 12;10:925538. (PMID: 36186657) Thyroid. 2015 Jul;25(7):716-59. (PMID: 25900731) J Pediatr. 2014 Jun;164(6):1481-5. (PMID: 24630354) Thyroid. 2020 Jul;30(7):1017-1024. (PMID: 31964278) Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1374-1385. (PMID: 34664092) Front Endocrinol (Lausanne). 2021 Nov 09;12:743310. (PMID: 34858329) J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9. (PMID: 16684830) Biomedicines. 2022 Aug 08;10(8):. (PMID: 36009464) Endocrine. 2021 Sep;73(3):617-624. (PMID: 33755880) Transl Cancer Res. 2020 Aug;9(8):4676-4685. (PMID: 35117831) CA Cancer J Clin. 2020 Nov;70(6):443-459. (PMID: 32940362) Front Endocrinol (Lausanne). 2022 Jun 02;13:872527. (PMID: 35721746) Endocrine. 2020 Jul;69(1):113-125. (PMID: 32189188) Eur Thyroid J. 2022 Nov 29;11(6):. (PMID: 36228315) Clin Nucl Med. 2023 Feb 1;48(2):158-167. (PMID: 36240802) J Clin Endocrinol Metab. 2016 May;101(5):1970-9. (PMID: 26930182) Front Endocrinol (Lausanne). 2021 May 10;12:667544. (PMID: 34040584) Clin Exp Med. 2023 Oct;23(6):2193-2200. (PMID: 36348126) Endocr Pract. 2020 May;26(5):499-507. (PMID: 31968190) J Clin Endocrinol Metab. 2023 Jan 17;108(2):306-314. (PMID: 36226635) J Clin Oncol. 2022 May 1;40(13):1439-1449. (PMID: 35044839) J Clin Endocrinol Metab. 2012 Aug;97(8):2754-63. (PMID: 22639291) Endocr Pract. 2019 Sep;25(9):877-886. (PMID: 31170365) Ann Nucl Med. 2015 Feb;29(2):184-9. (PMID: 25404419) Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1941-59. (PMID: 18670773) Pediatr Blood Cancer. 2017 Nov;64(11):. (PMID: 28436606) J Clin Endocrinol Metab. 2008 Mar;93(3):809-14. (PMID: 18160464) Cancer. 2019 Jul 15;125(14):2497-2505. (PMID: 31012956) Thyroid. 2016 Jan;26(1):1-133. (PMID: 26462967) Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2466-2475. (PMID: 33416957) J Clin Endocrinol Metab. 2017 Mar 1;102(3):793-800. (PMID: 27809646) CA Cancer J Clin. 2018 Jan;68(1):55-63. (PMID: 29092098) |
فهرسة مساهمة: | Keywords: children and adolescents; differentiated thyroid cancer; prognosis; radioiodine therapy; therapeutic response; thyroglobulin |
المشرفين على المادة: | 0 (Iodine Radioisotopes) 9010-34-8 (Thyroglobulin) |
تواريخ الأحداث: | Date Created: 20240806 Date Completed: 20240806 Latest Revision: 20240807 |
رمز التحديث: | 20240807 |
مُعرف محوري في PubMed: | PMC11298371 |
DOI: | 10.3389/fendo.2024.1419141 |
PMID: | 39104809 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1664-2392 |
---|---|
DOI: | 10.3389/fendo.2024.1419141 |